TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02392468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching BI 409306 50 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 409306 50 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 409306 50 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 25 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 50 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 409306 50 mg
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 50 mg
Description: Film-coated tablet
Study: NCT01689766

Intervention type: DRUG
Group type: OTHER
Intervention: Technetium Tc 99m EC20
Study: NCT00544804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study: NCT00530491

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast track lung surgery
Description: fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast track lung surgery
Description: fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
Study: NCT00444418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, 100 mg. oral dosage, daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone, 100 mg. oral dosage, daily for 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
Study: NCT00735098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KBA exercise
Description: KBA exercise protocol, 3 times per week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training exercise
Description: strength training exercise, 3 times per week for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KBA and strength training
Description: KBA and strength training exercise, 3 times per week for 8 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: 8 week control group
Study: NCT04703062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 1
Description: It is planned to do exercises for 50 minutes a day, 2 days a week during 8 weeks with physiotherapist. It will be planned individually according to the needs of the patients. Exercises will progress in the following weeks by changing the number of repetitions, the amount of resistance and the amount of time. Counseling about physical activity and the suggested sports activity will be provided. In daily living activities ergonomics and joint protection principles will be taught. Informing Family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group 2
Description: Counseling about physical activity and the suggested sports activity will be provided.Patients make aerobic and strengthening exercises by himself based on physiotherapist's suggestions. Informing Family about; Why are the exercises necessary To what extent the families should be protective The harmful effects of inactivity There will be information about the resting-activity cycle when there is bleeding.
Study: NCT04290260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of breast bra
Description: Patients will use a breast from admission to hospital discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (not use of bra)
Study: NCT00333970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: individual cognitive training
Study: NCT03582852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of genital prolapse
Description: Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment of genital prolapse
Description: Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
Study: NCT00956462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac (NSAID) versus Dexamethasone (steroid)
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac (NSAID) versus Dexamethasone (steroid)
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device
Study: NCT02302755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP10
Description: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
Study: NCT00049140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioluminescence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study: NCT02637648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: parallel Group administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: parallel Group administration
Study: NCT00829062

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Continuous glucose glucose sensor- physician ordered
Description: Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
Study: NCT01995422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program
Description: One hour sessions of active walking occurring three times a week during three months
Study: NCT04439812

Intervention type: OTHER
Intervention: Observation
Description: The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.

Intervention type: OTHER
Intervention: Observation
Description: The primary aim of this study was to evaluate the influence of positive margins on the tumour's recurrence and OS after gastrectomy for GC. The secondary outcome was to analyse the possible confounding factors that could affect the recurrence and OS after gastrectomy.
Study: NCT02952898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC 695
Description: GDC 695 is a topical gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Gel, 3%
Description: Diclofenac sodium gel, 3% is an FDA-approved drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
Study: NCT04173832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianqi Pingchan Granule Combined With Amantadine
Description: Tianqi Pingchan Granule and Amantadine are given to patients simultaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Combined With Amantadine
Description: Placebo and Amantadine are given to patients simultaneously
Study: NCT03360591

Intervention type: DEVICE
Group type: OTHER
Intervention: Physiologically-guided strategy
Description: The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiologically-guided strategy
Description: The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches \>2.5mm, with a % coronary stenosis\>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR \>0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values \>0.80 that show a discrepancy with positive (\<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy
Study: NCT00110526

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad.hIL-12
Description: Ad.hIL-12 intraprostatic injection IND
Study: NCT04020757

Intervention type: DEVICE
Group type: OTHER
Intervention: variation in dialysis bicarbonate
Description: 35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zone Perfect bar
Description: 16g protein supplement given during first 30 mins of dialysis on last testing day
Study: NCT03603379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C225-ILs-dox
Description: C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
Study: NCT00229983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
Study: NCT01716715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT01018589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix cream
Description: We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application.
Study: NCT02748967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive single dose of Placebo on Day 1.
Study: NCT01006694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation + Medication
Description: Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Antidepressant Medication
Description: Guideline Antidepressant Medication, following the VN National Mental Health plan.
Study: NCT02079545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-AI)
Description: Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-U)
Description: Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab (SC injection with PFS-AI)
Description: Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
Study: NCT02403492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP
Description: All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP
Description: All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP, Continuation
Description: Participants will be randomized to continue cPAP for a 2 week period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cPAP, Discontinuation
Description: Participants will be randomized to discontinue cPAP for a 2 week period
Study: NCT02555683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 450 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT03465306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided
Description: Self-guided refers to any contact between the participants and a therapist or coach.
Study: NCT02314702

Intervention type: DEVICE
Intervention: PROFEMUR® L Revision Femoral Stem
Description: Revision Total Hip Arthroplasty
Study: NCT01367210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc, Darunavir/r
Description: Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: current antiretroviral therapy with 3 drugs
Description: To continue the assumption of previous HAART
Study: NCT01877265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Study: NCT01245660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAPATINIB
Description: Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
Study: NCT02949037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health Care Environment (MHCE)
Description: An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
Study: NCT01235143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
Study: NCT01947582

Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle foot orthosis
Description: The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
Study: NCT02082275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OB Nest
Description: * Reduction in the number of clinic office visits~* Assignment to a specific nursing care team~* Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~* Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~* Augmentation of in-person visits between care providers and patients with video conversations.~* Maternal outcomes will be monitored through surveys and questionnaires.
Study: NCT01224860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
Study: NCT00522197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: multi-herbal agent ACAPHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT03098953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: one drop per eye for each eye
Study: NCT04645875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit regimen
Description: See Sit regimen arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SitLess regimen
Description: See SitLess regimen arm description
Study: NCT01560364

Intervention type: OTHER
Intervention: renal replacement therapy
Description: Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.